Skip to main content
Oxford University Hospitals NHS Foundation Trust

This site is best viewed with a modern browser. You appear to be using an old version of Internet Explorer.

Developing a vaccine to prevent RSV, a cause of serious respiratory infections in infants

Trial categories: Immunity; Infection; Vaccines

Sponsoring organisation: Janssen Vaccines & Prevention B.V

A Randomized, Double-blind, Phase 1/2a Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.preF in Adults 18 to 50 Years of Age and RSV-Seropositive Toddlers 12 to 24 Months of Age

The Oxford Vaccine Group at the University of Oxford would like to invite you and your child to take part in a study of a new vaccine against Respiratory Syncytial virus (RSV), one of the most important causes of serious respiratory illness in infants and children.

If your child is 12 to 24 months old and are in good health then they may be eligible to take part in this study.

The study involves:

  • Vaccination with 2 doses of an investigational RSV vaccine or placebo 1 month apart
  • We would use local anaesthetic cream on the skin to reduce any discomfort from the blood sampling
  • Nose swabs
  • 7-9 visits at home over a 30-week period, and regular phone calls
  • You would have 24 hour telephone access to a paediatrician should you have any concerns following immunisation

Taking part in this study is voluntary. For further information, please visit:

or contact us on:

Back to list of trials